Armistice Capital Among Funds Using Options Alongside Equity in Biopharma Portfolios
A subset of institutional investors in biotechnology and biopharmaceuticals has moved beyond straightforward equity positions to incorporate options contracts as part of their portfolio strategy. Armistice Capital, which manages more than $7 billion and carries significant healthcare exposure, is among the funds that combine equity stakes with listed options to structure positions around anticipated clinical and regulatory catalysts.Armistice's...